미국의 제제 개발 아웃소싱 시장 규모, 점유율, 동향 분석 리포트 : 서비스별, 제제별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Market Size & Trends:

The U.S. formulation development outsourcing market size was estimated at USD 8.87 billion in 2024 and is projected to grow at a CAGR of 8.3% from 2025 to 2030. This growth is driven by increasing demand for innovative pharmaceutical and biotech products, rising R&D costs, and a need for specialized expertise. Outsourcing formulation development is an attractive option for companies looking to streamline their R&D processes, reduce costs, and access a wider range of resources.

The surge in R&D by pharmaceutical and biotechnology firms is a major driver propelling the demand for outsourced formulation development services. Over the past two decades, R&D spending and new drug launches have increased, leading to cost reduction and accelerated processes through outsourcing. This rising demand has prompted contract service providers to expand their capacities, fostering the growth of the U.S. formulation development outsourcing industry. Consequently, these factors substantially contribute to market expansion.

Drug formulation relies heavily on trial-and-error methods to predict optimal formulations, which can be costly, time-consuming, and labor-intensive. To address the need for reducing expenses on new Active Pharmaceutical Ingredients (APIs) and overall healthcare costs in the pharmaceuticals market, it is crucial to estimate preferred formulations. This helps the industry identify efficient drug development approaches. Consequently, the pharmaceutical and biotechnology sector extensively outsources these services to contract manufacturers to streamline costs and processes.

Advancements in technology drive innovations encourage companies to invest in discovering new compounds and developing blockbuster drugs. This leads to an increase in generic manufacturers and a growing pharmaceutical market, driven by unmet needs for various disorders and rising R&D activities for orphan therapies.

U.S. Formulation Development Outsourcing Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. formulation development outsourcing market report based on service, formulation, therapeutic area, and end use:

• Service Outlook (Revenue, USD Million; 2018 - 2030)
• Pre-formulation
• Formulation Development
• Formulation Outlook (Revenue, USD Million; 2018 - 2030)
• Oral
• Injectable
• Topical
• Others
• Therapeutic Area Outlook (Revenue, USD Million; 2018 - 2030)
• Oncology
• Infectious Disease
• Neurology
• Hematology
• Respiratory
• Cardiovascular
• Dermatology
• Others
• End Use Outlook (Revenue, USD Million; 2018 - 2030)
• Pharmaceutical and Biopharmaceutical Companies
• Government and Academic Institutes
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Formulation
  • 1.2.3. Therapeutic Area
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Formulation Development Outsourcing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Formulation Development Outsourcing Market: Service Business Analysis

• 4.1. Service Market Share, 2024 & 2030
• 4.2. Service Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Pre-formulation
  • 4.4.1. Pre-formulation Market, 2018 - 2030 (USD Million)
• 4.5. Formulation Development
  • 4.5.1. Formulation Development Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Formulation Development Outsourcing Market: Formulation Business Analysis

• 5.1. Formulation Market Share, 2024 & 2030
• 5.2. Formulation Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Formulation Market, 2018 - 2030 (USD Million)
• 5.5. Injectable
  • 5.5.1. Injectable Formulation Market, 2018 - 2030 (USD Million)
• 5.6. Topical
  • 5.6.1. Topical Formulation Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Other Formulation Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Therapeutic Area Development Outsourcing Market: Therapeutic Area Business Analysis

• 6.1. Therapeutic Area Market Share, 2024 & 2030
• 6.2. Therapeutic Area Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Formulation Development Outsourcing Market, for Oncology, 2018 - 2030 (USD Million)
• 6.5. Infectious Disease
  • 6.5.1. Formulation Development Outsourcing Market, for Infectious Disease, 2018 - 2030 (USD Million)
• 6.6. Neurology
  • 6.6.1. Formulation Development Outsourcing Market, for Neurology, 2018 - 2030 (USD Million)
• 6.7. Hematology
  • 6.7.1. Formulation Development Outsourcing Market, for Hematology, 2018 - 2030 (USD Million)
• 6.8. Respiratory
  • 6.8.1. Formulation Development Outsourcing Market, for Respiratory, 2018 - 2030 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Formulation Development Outsourcing Market, for Cardiovascular, 2018 - 2030 (USD Million)
• 6.10. Dermatology
  • 6.10.1. Formulation Development Outsourcing Market, for Dermatology, 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Formulation Development Outsourcing Market, for Others, 2018 - 2030 (USD Million)

Chapter 7. U.S. Formulation Development Outsourcing Market: End Use Business Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. End Use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical and Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Segment Market, 2018 - 2030 (USD Million)
• 7.5. Government and Academic Institutes
  • 7.5.1. Government and Academic Institutes Segment Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. SGS Societe Generale de Surveillance SA
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Intertek Group plc
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Recipharm AB
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Lonza
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Charles River Laboratories
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Eurofins Scientific
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Element
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Labcorp
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Thermo Fisher Scientific Inc
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Catalent, Inc
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives